Omni Bio Pharmaceutical — Across America Financial Services — Merger or Acquisition (March 2009)
23 slides from Omni Bio Pharmaceutical's merger presentation, Mar 4, 2009

Slide 1: Omni Bio: Broad Spectrum Therapeutics Targeting Bacterial and Viral Diseases
Omni Broad Spectrum Therapeutics Targeting Bacterial and Viral Diseases, Biohazards and Transplant Rejection with Diabetes as the first Targeted Disease Maren 4, 2009 Omni Forward Looking Statements “This presentation is fr information purposes only. We are not curently a publicly ‘poring company, a

Slide 2: Omni Bio is currently developing clinical applications
Omni Bio is currently developing clinical applications using a broad patent portfolio licensed from the University of Colorado utilizing an FDA approved, off-patent drug. Alpha 1 Antitrypsin (“AAT”), to treat a variety of new indications Omni Bio's mission is to monetize sponsored research and licen

Slide 3: Separate Licenses with the University of Colorado
3 Separate Licenses with the University of Colorado 1) In.2008, we licensed filed but not issued patents related to AAT use for treating bacterial infection including Bacterial Pneumonia, TB, and Anthrax infection 2) In 2008, we licensed an existing patent for the treatment of viral infections inclu

Slide 4: Initial Targeted Indications Using AAT
Initial Targeted Indications Using AAT — Anthrax (prophylaxis and treatment) - Dr. Shapiro — Influenza (prophylaxis and treatment) - Dr. Shapiro — Graft/Transplant Rejection (primary treatment) - Dr. Dinarello] — Diabetes (secondary or primary treatment) - Dr. Dinarello Other Potential Applications

Slide 5: Anthrax spores
Anthrax spores is age ue “1-2 uM in diameter-ideal for lung infection. “Spore form makes this an attractive bioweapon. Spores can survive drying, heat, UV and gamma irradiation, several disinfectants. May survive thousands of years, -Aerosolized spores remain infectious after traveling 60 miles. Omn

Slide 6: Anthrax goes postal
Anthrax goes postal " Omni Anthrax goes postal Spores sent in letters through US Postal Service Sept 2001 -5-7 letters. All originated from Trenton, NJ. -2.0 grams of spores in the Daschle letter, 101/10 spores/gram (100 million-1 trilion/gram, don't try this at home). -22.with confirmed or suspecte

Slide 7: US postal service attacks: what was learned
US postal service attacks: what was learned 1. Anthrax is a formidable weapon of bioterrorism 2. Inhalation anthrax mortality=5/11 (46%, <<quoted 80-95%). 3. Exposure--(4d)—-symptoms/signs--(3.5d)-medical care sought 4. Presentation + Fever (>100.4°F), pulse>100, sweats + CXR. abnormal in 100% + Blo

Slide 8: AAT blocks anthrax toxin-induced cell death
AAT blocks anthrax toxin-induced cell death Omni = 3 ty 3 oO ° (statistically significant) Anthrax toxin alone 1 2 3 5 7 Anthrax toxin + AAT (mg/ml) Mice with human AAT gene (AAT**) are protected from anthrax toxin-induced death Omni Percent survival (statistically significant) “BE AAT*” (N=17)

Slide 9: Bird flu hits Florida!
Bird flu hits Florida! 7 Omni Influenza -Each year in the U.S. -5-20% of the population contracts FLU +15-60 million people -200,000 pgople hospitalized -41,000 deaths. “Cost to theleconomy=$90 billion. “Avian (bird) FILU: +400 cases |worldwide....so far -Mortality=60% -Worldwide|FLU pandemic predic

Slide 10: AAT deficiency is a risk factor for FLU infection
AAT deficiency is a risk factor for FLU infection (statistically significant) ’ : Percent without influenza —— Other (n=112) = p=0.0012 4 AAT deficient (n=28) 0 500 1,000 1,500 2,000 2,500 3,000 3,500 Omni AAT protects cells from FLU infection Flu alone Flu + AAT - 2 Omni

Slide 11: AAT inhibits FLU effects in mice infected with influenza
AAT inhibits FLU effects in mice infected with influenza (statistically significant) Se 7 eo wn 2 4 Days postinfection a Omni Survival: mice exposed to FLU (statistically significant) 4567 eo HR 4 Days postinfection Omni

Slide 12: AAT therapy for anthrax or FLU
AAT therapy for anthrax or FLU 1. Current anthrax and FLU treatments are of modest efficacy. There is an unmet need. Use as both treatment and prophylaxis. Should have efficacy for all anthrax strains (including “weaponized variants), as well as all Influenza types including “bird FLU” and “weaponiz

Slide 13: Insulin-producing islets are buried in the pancreas
Insulin-producing islets are buried in the pancreas istets are small ‘islands’ of ‘cells producing insulin for the entire body islets have a blood supply equal to that of the brain Omni Omni In both type 1 and type 2 diabetes, there is progressive loss of insulin production due to death of cells in

Slide 14: Human islets isolated from an organ donor are damaged
Human islets isolated from an organ donor are damaged by harmful cytokines. Cytokines: Chemokines: IL-1B WL8 Interferon-y MCP low oxygen Nitric Oxide Omni Human islets: Effect of cytokine stimulation and protection by AAT ‘human islets die and disintegrate _islets survive in the presence of AAT We I

Slide 15: AAT monotherapy resulted in immunologic tolerance
Omni 0 16 32 64 0 4 81632 S Nitric Oxide uM ae 1L-6 peas om 0 4 81632 04 81632 Omni What we observed is an amazing finding: AAT monotherapy resulted in immunologic tolerance, that is, the mice no longer reacted to the foreign islets as foreign but rather as self. The non-immunosuppressant agent (AAT

Slide 16: a1-Antitrypsin monotherapy prolongs islet allograft survival in mice
2005 c1-Antitrypsin monotherapy prolongs islet allograft survival in mice 2008 a1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice {ctw Mark Mra ene’ Naan Defer, Anew hag {ese Stapeor and cares A Dranio™ Omni Test of the hypothesis: does AAT treatment p

Slide 17: Is AAT an immunosuppressive therapy?
Is AAT an immunosuppressive therapy? In mice, immune tolerance is specific, demonstrating a non-immunosuppressive mechanism. For over 20 years use in thousands of humans, no evidence of infections or cancer, heart disease or degenerative diseases. Omni ‘let transplant: ‘Complete rejection i i i Omni

Slide 18: How does AAT work?
Day 85 of AAT therapy. The transplanted islets are intact, producing insulin, while the immune attack is held at bay. The transplant is surrounded by a cuff of immune cells that do not invade the foreign transplant. The immune cells appear to be paralyzed from entering and attacking the transplant.

Slide 19: Diabetes is a costly chronic disease
Diabetes is a costly chronic disease with the end-point being cardiovascular disease. Despite improved and tight control of blood sugar, death from cardiovascular disease (heart attacks and strokes) has not been reduced +15 Million Type 1 Diabetics in US Alone (type 1 and candidates for transplantat

Slide 20: AAT as adjunct therapy for human transplantation
AAT as adjunct therapy for human transplantation Since AAT is effective experimental islet transplantation and results in specific immune tolerance, is AAT also effective in bone marrow transplantation? If AAT monotherapy results in specific immune tolerance, is AAT likely to reduce current immunosu

Slide 21: AAT in type 1 and type 2 diabetes
Since AAT protects mouse islets from the toxicity of cytokines (2005) and in the Non-Obese Diabetic (NOD) mouse (2008) results in beta cell regeneration, is AAT a candidate for use in human type | diabetes? Immune Tolerance Network (ITN) will initiate a study in late onset type 1 diabetes. Since AAT

Slide 22: The unusual advantages of AAT in transplantation and diabetes
The unusual advantages of AAT in transplantation and in diabetes: 1. 20 year substantiated safety record in thousands of patients Validated pre-clinical models in vitro and in animals FDA approval for studies Availability of human AAT Likely IRB approval, patient consent based on past use RON “a Omn

Slide 23: Proposed Capital Structure
Proposed Capital Structure Public Vehicle Symbol (OTCBB) AAFS Stock Price (3-03-09) $.50 Shares Outstanding 21,748,632 Shares Fully Diluted 31,976,133 University of Colorado’s Holdings 6% Target Close Date March 2009 “Assumes §1.5m private placement consisting of 1 share of common, 2 warrants ex at
Source: SEC EDGAR · 8-K filed Mar 4, 2009
More decks from Omni Bio Pharmaceutical Inc
Investor Presentation (September 2014)27 slides · Sep 11, 2014
Investor Presentation (June 2014)26 slides · Jun 3, 2014
Investor Presentation (September 2013)24 slides · Sep 9, 2013
Investor Presentation (July 2013)27 slides · Jul 2, 2013
Investor Presentation (February 2013)20 slides · Feb 12, 2013
Investor Presentation (March 2012)25 slides · Mar 20, 2012